Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients

Leukemia

Volumn 29, Issue 2, 2015, Pages 297-303

  Wesolowska Andersen A ^a   Borst, L ^b   Dalgaard, M D ^a   Yadav, R ^a   Rasmussen, K K ^b   Wehner, P S ^c   Rasmussen, M ^d   Orntoft, T F ^e   Nordentoft, I ^e   Koehler, R ^f   Bartram, C R ^f   Schrappe, M ^g   Sicheritz Ponten, T ^a   Gautier, L ^a   Marquart, H ^h   Madsen, H O ^h   Brunak, S ^a   Stanulla, M ^b   Gupta, R ^a   Schmiegelow, K ^b,i  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b University of Copenhagen   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ESTROGEN RECEPTOR ALPHA; GLUCOCORTICOID; LAMIN B; MATRILYSIN; MYELOPEROXIDASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CYTOGENETICS; DANISH CITIZEN; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GERMAN (CITIZEN); HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; ADOLESCENT; DENMARK; GENETIC POLYMORPHISM; GENETICS; GENOMICS; GENOTYPE; GERMANY; HUMAN GENOME; INFANT; MINIMAL RESIDUAL DISEASE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; GENOME, HUMAN; GENOMICS; GENOTYPE; GERMANY; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; TREATMENT OUTCOME;

EID: 84922503241     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.205     Document Type: Article

References (25)

1. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005; 293: 1485-1489.
2. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics in fluence treatment effi cacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008; 30: 831-849.
3. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012; 120: 1165-1174.
4. Forestier E, Schmiegelow K. The incidence peaks of the childhood acute leukemias refl ect speci fic cytogenetic aberrations. J Pediatr Hematol Oncol 2006; 28: 486-495.
5. Davies SM, Borowitz MJ, Rosner GL, Ritz K, Devidas M, Winick N et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111: 2984-2990.
6. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105: 4752-4758.
7. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S et al. The association of reduced folate carrier 80G4A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 2010; 115: 4671-4677.
8. Yang JJ, Cheng C, Devidas M, Cao X, Campana D, Yang W et al. Genome-wide association study identi fies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012; 120: 4197-4204.
9. Wesolowska A, Dalgaard MD, Borst L, Gautier L, Bak M, Weinhold N et al. Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant SNPs in childhood acute lymphoblastic leukemia. Leukemia 2011; 25: 1001-1006.
10. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
11. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van dV V, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22 : 771-782.
12. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
14. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467: 52-58.
15. Besag J, Mondal D. Exact goodness-of- fit tests for Markov chains. Biometrics 2013; 69: 488-496.
16. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G et al. The Reactome pathway knowledgebase. Nucleic Acids Res 2014; 42: D472-D477.
17. Matthews BW. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta 1975; 405: 442-451.
18. Thorn CF, Klein TE, Altman RB. PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol 2013; 1015: 311-320.
19. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
20. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
21. Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron 2009; 2(Suppl 1): 205-214.
22. Correa RG, Milutinovic S, Reed JC. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci Rep 2012; 32: 597-608.
23. Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallbook H et al. Risk group assignment differs for children and adults 1-45yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol 2013; 90: 404-412.
24. Frandsen TL, Heyman M, Abrahamsson J, Vettenranta K, aasberg A, Vaitkeviciene G et al. Complying with the European Clinical Trials Directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. Eur J Cancer 2014; 50 : 251-259.
25. Lund B, Wesolowska-Andersen A, Lausen B, Borst L, Rasmussen KK, Muller K et al. Host genome variations and risk of infections during induction treatment for childhood acute lymphoblastic leukaemia. Eur J Haematol 2014; 92: 321-330.